Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses the importance of using novel approaches to predict patient response to Bruton’s tyrosine kinase (BTK) inhibitor therapy. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.